Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes

Blood Pressure

Volumn 7, Issue 3, 1998, Pages 170-175

  Trenkwalder, Peter ^a,e   Dahl, Ketil ^b   Lehtovirta, Mikko ^c   Mulder, Henk ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Kiopmannsgt   (Norway)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Medisch Onderzoekcentrum Good C   (Netherlands)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Angiotensin receptor blockers; Candesartan cilexetil; Diabetes mellitus; Glycosylated hemoglobin; Serum lipids

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CANDESARTAN HEXETIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BORDERLINE HYPERTENSION; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EPISTAXIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEADACHE; HEART RATE; HEMOGLOBIN DETERMINATION; HUMAN; LIPID BLOOD LEVEL; LUNG CARCINOMA; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEINS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 0031710154     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370598437385     Document Type: Article

References (25)

1. Kaplan NM. Combination therapy for systemic hypertension. Am J Cardiol 1995; 76: 595-7.
2. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary artery disease: overall findings and differences by age for 316 099 white men. Arch Intern Med 1992; 152: 56-64.
3. Kannel WB. Potency of vascular risk factors as a basis for antihypertensive therapy. Eur Heart J 1992; 13 (Suppl G): 34-42.
4. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991; 67: 26B-35B.
5. Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
6. Madu EC, Reddy RC, Madu AN, Anyaogu C, Harris T, Fraker TD Jr. Review: the effects of antihypertensive agents on serum lipids. Am J Med Sci 1996; 312(2): 76-84.
7. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 134: 203-9.
8. Working Group on Management of Patients with Hypertension and High Blood Cholesterol. National Education Program's Working Group report on the management of patients with hypertension and high blood pressure. Ann Intern Med 1991; 114: 224-37.
9. Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. JAMA 1993; 270: 713-24.
10. Weber MA, Byyny RL, Pratt H, Faison EP, Snavely DB, Goldberg AI, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155: 405-11.
11. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med 1996; 156: 1957-65.
12. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
13. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997; 319: 137-46.
14. Hubner R, Elmfeldt D, George M, Olofsson B. Candesartan cilexetil, a novel angiotensin II antagonist, provides dose-dependent antihypertensive effect with maintained tolerability. Am J Hypertens: in press.
15. Chow L, De Gasparo M, Levens N. Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors. Eur J Pharmacol 1995; 282: 77-86.
16. Moan A, Risanger T, Eide I. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3: 185-8.
17. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 820-45.
18. Laakso M, Karjalainen L, Lempiäinen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392-6.
19. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195-8.
20. Rett K, Wicklmayr M, Dietze G, Mehnert H. Clinical studies with ACE-inhibitors in diabetes. Horm Metab Res 1989; 22 (Suppl): 69-74.
21. Moan A, Hoieggen A, Eide I. Metabolic effects of antihypertensive treatment with the angiotensin II receptor antagonist losartan. Ricerca Scientifica ed Educazione Permanente 1995; (Suppl 103): 126, abstract 551 (Seventh European Meeting on Hypertension, Milan).
22. Sami H, Laurel C, Anderson PW. Effects of losartan treatment in hypertensive patients. J Invest Med 1995; 43 (Suppl 1): 199A (abstract).
23. Middeke M, Holzgreve H. Review of major intervention studies in hypertension and hyperlipidemia: focus on coronary heart disease. Am Heart J 1988; 116; 1708-12.
24. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5.
25. Mackay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-85.